Product Description
Mechanisms of Action: SERT Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Italy | Jordan | Korea | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Erectile Dysfunction|Premature Ejaculation|Obstetric Labor, Premature
Phase 3: Premature Ejaculation|Obstetric Labor, Premature|Erectile Dysfunction|Sexual Dysfunction, Physiological
Phase 2: Obstetric Labor, Premature|Premature Ejaculation
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ChiCTR2200057359 | N/A |
Recruiting |
Premature Ejaculation |
2024-10-01 |
|
| ChiCTR2200066928 | N/A |
Not yet recruiting |
Premature Ejaculation |
2024-09-30 |
|
| ChiCTR2100054538 | N/A |
Recruiting |
Premature Ejaculation |
2024-07-01 |
|
| CTR20230570 | N/A |
Completed |
Premature Ejaculation |
2023-05-16 |